Cantabio Pharmaceuticals is dedicated to the discovery and development of innovative therapies targeting neurodegenerative diseases, with a primary focus on Parkinson's and Alzheimer's diseases. Their research and development efforts center around identifying and validating novel therapeutic targets, such as DJ-1 and Tau proteins, which play critical roles in the pathogenesis of these debilitating conditions. The company employs a combination of small molecule drug discovery and protein engineering approaches to develop pharmacological chaperones and protein replacement therapies. These therapies aim to address the underlying biochemical stress and protein misfolding that contribute to disease progression. By targeting these fundamental mechanisms, Cantabio seeks to develop disease-modifying treatments that can improve patient outcomes and quality of life. The company's pipeline includes several preclinical programs, each designed to address specific aspects of neurodegeneration and offer potential therapeutic benefits for patients suffering from these devastating illnesses.